CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• People with metastatic triple-negative breast cancer need effective treatment options as early as possible, and if authorized, Trodelvy plus Keytruda would build on the recent approval of Trodelvy monotherapy and help establish a Trodelvy-based approach as a first-line treatment option across PD-L1 status.

  60% confidence

Cited in these Via News reports

• Cancer's two big bets: a personalised vaccine that held melanoma at bay, and AI that designs the drugs. Here is what is verified and what is not →